• Beatriz Bustamante
  • Pablo E. Campos


Mycetoma is a chronic subcutaneous infection that develops after one of the multiple etiologic microorganisms is inoculated into a site of skin trauma. Although mycetoma is primarily a subcutaneous disease, it can involve bone and lymph nodes by contiguous spread. Mycetoma shows three clinical characteristics: tumor, sinuses, and grains. The tumor results as a consequence of a progressive and relatively painless swelling. Sinuses are a characteristic of the disorder; they can be absent in early stages, but later develop and drain purulent material and grains. Grains are colonies of the causative agent and can be black, white, or red. Mycetoma can be caused by a variety of fungal agents (eumycetoma), or filamentous gram-positive branching bacteria belonging to the aerobic Actinomycetales (actinomycetoma).


Antifungal Agent Sinus Tract Aspergillus Species Bone Involvement Secondary Bacterial Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Godfrey J. Disease of the foot not hitherto described. Lancet. 1846;1:593–4.Google Scholar
  2. 2.
    Carter HV. On a new and striking form of fungus disease, principally affecting the foot, and prevailing endemically in many parts of India. Trans Med Phys Soc Bombay. 1860;6:104–42.Google Scholar
  3. 3.
    Brumpt E. Les mycétomes. Arch Parasitol. 1906;10:489–564.Google Scholar
  4. 4.
    Pinoy E. Actinomycoses and mycetomas. Bull Inst Pasteur. 1913;11:929–38.Google Scholar
  5. 5.
    Chalmers AJ, Christopherson JB. A Sudanese actinomycosis. Ann Trop Med Parasitol. 1916;10:223–82.Google Scholar
  6. 6.
    Chalmers AJ, Archibald RG. A Sudanese maduromycosis. Ann Trop Med Parasitol. 1916;10:169–222.Google Scholar
  7. 7.
    McGinnis MR, Fader RC. Mycetoma: A contemporary concept. Infect Dis Clin N Am. 1988;2:939–54.Google Scholar
  8. 8.
    Gilgado F, Cano J, Gene J, Sutton DA, Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol. 2008;46:766–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Harun A, Perdomo H, Gilgado F, Chen SC, Cano J, Guarro J, et al. Genotyping of Scedosporium species: a review of molecular approaches. Med Mycol. 2009;47:406–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Hay RJ, Mahgoub ES, Leon G, Al-Sogair S, Welsh O. Mycetoma. J Med Vet Mycol. 1992;30 suppl 1:41–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Mariat F. On the geographic distribution and incidence of mycetoma agents. Bull Soc Pathol Exot Filiales. 1963;56:35–45.PubMedGoogle Scholar
  12. 12.
    Klokke AH, Swamidasan G, Anguli R, Verghese A. The causal agents of mycetoma in South India. Trans R Soc Trop Med Hyg. 1968;62:509–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Gumaa SA, Mahgoub ES, El Sid MA. Mycetoma of the head and neck. Am J Trop Med Hyg. 1986;35:594–600.PubMedGoogle Scholar
  14. 14.
    Hazra B, Bandyopadhyay S, Saha SK, Banerjee DP, Dutta G. A study of mycetoma in eastern India. J Commun Dis. 1988;30:7–11.Google Scholar
  15. 15.
    Venugopal PV, Venugopal TV. Treatment of eumycetoma with ketoconazole. Australas J Dermatol. 1993;34:27–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health. 2002;7:788–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Dieng MT, Sy MH, Diop BM, Niang SO, Ndiaye B. Mycetoma: 130 cases. Ann Dermatol Vénéréol. 2003;130:16–9.PubMedGoogle Scholar
  18. 18.
    Bakshi R, Mathur DR. Incidence and changing pattern of mycetoma in western Rajasthan. Indian J Pathol Microbiol. 2008;51:154–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Lavalle P. Mycetoma. In: Canizares O, Harman RRM, editors. Clinical Tropical Dermatology. 2nd ed. Boston: Blackwell Scientific Publication; 1992. p. 41–60.Google Scholar
  20. 20.
    Boiron P, Locci R, Goodfellow M, et al. Nocardia, nocardiosis and mycetoma. Med Mycol. 1998;36 Suppl 1:26–37.PubMedGoogle Scholar
  21. 21.
    Buot G, Lavalle P, Mariat F, Suchil P. Étude épidémiologique des mycétomes au Mexique. Bull Soc Pathol Exot. 1987;80:329–39.Google Scholar
  22. 22.
    Mahgoub ES. Mycetoma. In: Mahgoub ES, editor. Tropical mycoses. Beerse, Belgium: Janssen Research Council; 1989. p. 57–74.Google Scholar
  23. 23.
    Cooke WB, Kahler PW. Isolation of potentially pathogenic fungi from polluted water and sewage. Public Health Rep. 1955;70:689–94.PubMedGoogle Scholar
  24. 24.
    Borelli D. Madurella mycetomi y Madurella grisea. Arch Venez Med Trop Parasit Med. 1962;4:195–211.Google Scholar
  25. 25.
    Segretain G, Mariat F. Recherche sur la presence d’agents de mycètomes dans le sol et sur les épineux du Sénégal et de la Mauritanie. Bull Soc Pathol Exot. 1968;61:194–201.Google Scholar
  26. 26.
    Thirumalachar MJ, Padhye AA. Isolation of Madurella mycetomi from soil in India. Hindustan Antibiot Bull. 1968;10:314–8.PubMedGoogle Scholar
  27. 27.
    Segretain G, Mariat F. Recherche sur l´écologie des agents de mycètomes fungiques au Sénégal. 5th Congress International Society Human and Animal Mycology, Paris, France. pp. 153–154, 1971.Google Scholar
  28. 28.
    Segretain G. Epidémiologie des mycétomes. Ann Soc Belge Méd Trop. 1972;52:277–86.Google Scholar
  29. 29.
    Ahmed A, Adelmann D, Fahal A, Verbrugh H, van Belkum A, de Hoog S. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan. J Clin Microbiol. 2002;40:1031–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Van Amstel SR, Ross M, Van Den Berg SS. Maduromycosis (Madurella mycetomatis) in a horse. J South Afr Vet Assoc. 1984;55:81–3.Google Scholar
  31. 31.
    Lambrechts N, Collett MG, Henton M. Black grain eumycetoma (Madurella mycetomatis) in the abdominal cavity of a dog. J Med Vet Mycol. 1991;29:211–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Elad D, Orgal U, Yakobson B, et al. Eumycetoma caused by Curvularia lunata in a dog. Mycopathologia. 1991;116:113–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Guillot J, Garcia-Hermoso D, Degorce F, et al. Eumycetoma caused by Cladophialophora bantiana in a dog. J Clin Microbiol. 2004;42:4901–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Ramachandran PK. Mycetoma caused by an unknown fungus in Indian buffaloes (Bos bubalis). Ceylon Vet J. 1968;16:77–80.Google Scholar
  35. 35.
    Abbott P. Mycetoma in the Sudan. Trans R Soc Trop Med Hyg. 1956;50:11–24.PubMedCrossRefGoogle Scholar
  36. 36.
    Yu AM, Zhao S, Nie LY. Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations. Am J Trop Med Hyg. 1993;48:812–7.PubMedGoogle Scholar
  37. 37.
    Lee MW, Kim JC, Choi JS, Kim KH, Greer DL. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol. 1995;32:897–900.PubMedCrossRefGoogle Scholar
  38. 38.
    Fahal AH, el Toum EA, el Hassan AM, Mahgoub ES, Gumaa SA. The host tissue reaction to Madurella mycetomatis: new classification. J Med Vet Mycol. 1995;33:15–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Mahgoub ES, Gumma SA, El Hassan AM. Immunological status of mycetoma patients. Bull Soc Pathol Exot Filiales. 1977;70:48–54.PubMedGoogle Scholar
  40. 40.
    Bendl BJ, Mackey D, Al-Saati F, Sheth KV, Ofole SN, Bailey TM. Mycetoma in Saudi Arabia. J Trop Med Hyg. 1987;90:51–9.PubMedGoogle Scholar
  41. 41.
    van de Sande WW, Fahal A, Verbrugh H, van Belkum A. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol. 2007;179:3065.PubMedGoogle Scholar
  42. 42.
    Findlay GH, Vismer HF. Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in Madurella mycetomi infection. Br J Dermatol. 1974;91:297–303.PubMedCrossRefGoogle Scholar
  43. 43.
    van de Sande WW, de Kat J, Coppens J, et al. Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect. 2007;9:1114–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Green Jr WO, Adams TE. Mycetoma in the United States: a review and report of seven additional cases. Am J Clin Pathol. 1964;42:75–91.PubMedGoogle Scholar
  45. 45.
    Develoux M, Audoin J, Treguer J, Vetter JM, Warter A, Cenac A. Mycetoma in the Republic of Niger: clinical features and epidemiology. Am J Trop Med Hyg. 1985;38:386–90.Google Scholar
  46. 46.
    Castro LG, Belda Junior W, Salebian A, Cuce LC. Mycetoma: a retrospective study of 41 cases seen in Sao Paulo, Brazil, from 1978 to 1989. Mycoses. 1993;36:89–95.PubMedCrossRefGoogle Scholar
  47. 47.
    Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am. 2003;17:59–85.PubMedCrossRefGoogle Scholar
  48. 48.
    Daoud M, Ezzine Sebai N, Badri T, Mokhtar I, Fazza B, Kamoun MR. Mycetoma: retrospective study of 13 cases in Tunisia. Acta Dermatoven APA. 2005;14:153–6.Google Scholar
  49. 49.
    N’diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol. 2006;45:154–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Mirza SH, Gardezi AH, Khan Y, Wiqar MA. Subcutaneous facial mycosis in a child due to Madurella mycetomatis. J Pak Med Assoc. 2007;57:466–8.PubMedGoogle Scholar
  51. 51.
    Van Etta LL, Peterson LR, Gerding DN. Acremonium falciforme (Cephalosporium falciforme) mycetoma in a renal transplant patient. Arch Dermatol. 1983;119:707–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Meis JF, Schouten RA, Verweij PE, Dolmans W, Wetzels JF. Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient. Transpl Infect Dis. 2000;2:96–8.PubMedCrossRefGoogle Scholar
  53. 53.
    O’Riordan E, Denton J, Taylor PM, Kerr J, Short CD. Madura foot in the U.K.: fungal osteomyelitis after renal transplantation. Transplantation. 2002;73:151–3.PubMedCrossRefGoogle Scholar
  54. 54.
    Geyer AS, Fox LP, Husain S, et al. Acremonium mycetoma in a heart transplant recipient. J Am Acad Dermatol. 2006;55:1095–100.PubMedCrossRefGoogle Scholar
  55. 55.
    Satta R, Sanna S, Cottoni F. Madurella infection in an immunocompromised host. Int J Dermatol. 2000;39:939–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Neumeister B, Zollner TM, Krieger D, Sterry W, Marre R. Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses. 1995;38:271–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Mendez-Tovar LJ, de Bièvre C, Lopez-Martinez R. Effets des hormones sexuelles humaines sur le development in vitro des agents d´eumycetomes. J Mycol Med. 1991;1:141–3.Google Scholar
  58. 58.
    Lynch JB. Mycetoma in the Sudan. Ann R Coll Surg. 1964;35:319–40.Google Scholar
  59. 59.
    Destombes P, Mariat L, Rosati G, Segretain G. Les mycétomes en Somalie – conclusions d´une enquête menée de 1959 à 1964. Acta Trop. 1977;34:335–73.Google Scholar
  60. 60.
    Bustamante B, Campos PE. Eumycetoma. In: Kauffman CA, editor. Atlas of fungal infections. 2nd ed. Philadelphia: Current Medicine; 2007. p. 203.Google Scholar
  61. 61.
    Lopez-Martinez R, Mendez-Tovar LJ, Lavalle P, Welsh O, Saul A, Macotela Ruiz E. Epidemiology of mycetoma in Mexico: study of 2105 cases. Gac Méd Méx. 1992;128:477–81.PubMedGoogle Scholar
  62. 62.
    Elhardello OA, Adam ES, Adam I. Abdominal wall mycetoma presented as obstructed incisional hernia of cesarean section in Eastern Sudan. Infect Dis Obstet Gynecol. 2007, on-line publication (Article ID 74643, doi:10.1155/2007/74643).Google Scholar
  63. 63.
    Arbab MA, el Hag IA, Abdul Gadir AF, Siddik H el-R. Intraspinal mycetoma: report of two cases. Am J Trop Med Hyg. 1997;56:27–9.PubMedGoogle Scholar
  64. 64.
    Gumma SA, Satir AA, Shehata AH, Mahgoub ES. Tumor of the mandible caused by Madurella mycetomii. Am J Trop Med Hyg. 1975;24:471–4.Google Scholar
  65. 65.
    Aldrige J, Kirk R. Mycetoma of the eyelid. Br J Ophthalmol. 1940;24:211–2.CrossRefGoogle Scholar
  66. 66.
    Soni N, Gupta A, Shekhawat NS. Mycetoma - an unusual site. Surgery. 2000;127:709–10.PubMedCrossRefGoogle Scholar
  67. 67.
    Ly F, Develoux M, Deme A, Dangou JM, Kane A, Ndiaye B, et al. Tumoral mycetoma of the buttock. Ann Dermatol Vénéréol. 2000;127:67–9.PubMedGoogle Scholar
  68. 68.
    Ravisse P, Huerre M, De Bièvre C, et al. Les mycétomes en Mauritanie: Étude histologique de 150 cas. J Mycol Med. 1992;2:154–9.Google Scholar
  69. 69.
    Negroni R, Lopez-Daneri G, Arechavala A, Bianchi MH, Robles AM. Clinical and microbiological study of mycetomas at the Muniz hospital of Buenos Aires between 1989 and 2004. Rev Argent Microbiol. 2006;38:13–8.PubMedGoogle Scholar
  70. 70.
    Niño FL. Coexistencia de Madurella mycetomi y de M. grisea en una misma observacion de maduromicosis podal negra. Mycopathologia. 1962;16:323–32.PubMedGoogle Scholar
  71. 71.
    Mahgoub ES. Mycetoma. Semin Dermatol. 1985;4:230–9.Google Scholar
  72. 72.
    Camain R. Processus d´extension et de limitation des mycétomes africains. Bull Soc Pathol Exot. 1968;61:517–23.Google Scholar
  73. 73.
    El Hassan AM, Mahgoub ES. Lymph node involvement in mycetoma. Trans R Soc Trop Med Hyg. 1972;66:165–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Sharif HS, Clark DC, Aabed MY, et al. Mycetoma: comparison of MR imaging with CT. Radiology. 1991;178:865–70.PubMedGoogle Scholar
  75. 75.
    Tomimori-Yamashita J, Ogawa MM, Hirata SH, Fischman O, Michalany NS, Yamashita HK, et al. Mycetoma caused by Fusarium solani with osteolytic lesions on the hand: case report. Mycopathologia. 2001;153:11–4.CrossRefGoogle Scholar
  76. 76.
    McGinnis MR. Mycetoma. Dermatol Clin. 1996;14:97–104.PubMedCrossRefGoogle Scholar
  77. 77.
    Abd El-Bagi ME, Fahal AH. Mycetoma revisited: Incidence of various radiographic signs. Saudi Med J. 2009;30:529–33.PubMedGoogle Scholar
  78. 78.
    Czechowski J, Nork M, Haas D, Lestringant G, Ekelund L. MR and other imaging methods in the investigation of mycetomas. Acta Radiol. 2001;42:24–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Sarris I, Berendt AR, Athanasous N, Ostlere SJ. MRI of mycetoma of the foot: two cases demonstrating the dot-in-circle sign. Skeletal Radiol. 2003;32:179–83.PubMedCrossRefGoogle Scholar
  80. 80.
    Ahmed AO, Abugroun ES. Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol. 1998;36:850–1.PubMedGoogle Scholar
  81. 81.
    Fahal AH, Sheik HE, El Hassan AM. Pathological fractures in mycetoma. Trans R Soc Trop Med Hyg. 1996;90:675–67.PubMedCrossRefGoogle Scholar
  82. 82.
    Fahal AH, Sharfi AR, Sheik HE, El Hassan AM, Mahgoub ES. Internal fistula formation: An unusual complication of mycetoma. Trans R Soc Trop Med Hyg. 1996;90:550–2.PubMedCrossRefGoogle Scholar
  83. 83.
    Fahal AH, Yagi HI, El Hassan AM. Mycetoma-induced palatal deficiency and pharyngeal plexus dysfunction. Trans R Soc Trop Med Hyg. 1996;90:676–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Lopez-Cepeda LD, Mora-Ruiz S, Padilla-Desgarennes M del C, Ramos-Garibay JA. Small eumycetic mycetoma due to black grain. Arch Dermatol. 2005;141:783–4.CrossRefGoogle Scholar
  85. 85.
    Gabhane SK, Gangane N, Anshu. Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol. 2008;52:354–6.PubMedGoogle Scholar
  86. 86.
    Ahmed A, van de Sande W, Verbrugh H, et al. Madurella mycetomatis strains from mycetoma lesions in Sudanese patients are clonal. J Clin Microbiol. 2003;41:4537–41.PubMedCrossRefGoogle Scholar
  87. 87.
    Hemashettar BM, Siddaramappa B, Munjunathaswamy BS, et al. Phaeoacremonium krajdenii, a cause of white grain eumycetoma. J Clin Microbiol. 2006;44:4619–22.PubMedCrossRefGoogle Scholar
  88. 88.
    Desnos-Ollivier M, Bretagne S, Dromer F, et al. Molecular identification of black-grain mycetoma agents. J Clin Microbiol. 2006;44:3517–23.PubMedCrossRefGoogle Scholar
  89. 89.
    Hay RJ, Mackenzie DWR. The histopathological features of pale grain eumycetoma. Trans R Soc Trop Med Hyg. 1982;76:839–44.PubMedCrossRefGoogle Scholar
  90. 90.
    Hay RJ. Mycetoma (Maduromycosis). In: Strickland GT, editor. Hunter`s Tropical Medicine and Emerging Infectious Diseases. 8th ed. Philadelphia: W.B. Saunders; 2000. p. 537–41.Google Scholar
  91. 91.
    Chandler FW, Kaplan W, Ajello L. A Colour Atlas and Textbook of the Histopathology of Mycotic Diseases. London: Wolfe Medical Publication; 1980. p. 76–83. and 222–239.Google Scholar
  92. 92.
    Jackson JA, Kaplan W, Kaufman L, Standard P. Development of fluorescent-antibody reagents for demonstration of Pseudallescheria boydii in tissues. J Clin Microbiol. 1983;18:668–73.PubMedGoogle Scholar
  93. 93.
    Fenelon LE, Hamilton AJ, Figueroa JI, et al. Production of specific monoclonal antibodies to Aspergillus species and their use in immunohistochemical identification of aspergillosis. J Clin Microbiol. 1999;37:1221–3.PubMedGoogle Scholar
  94. 94.
    Choi JK, Mauger J, McGowan KL. Immunohistochemical detection of Aspergillus species in pediatric tissue samples. Am J Clin Pathol. 2004;121:18–25.PubMedCrossRefGoogle Scholar
  95. 95.
    Murray IG, Mahgoub ES. Further studies on the diagnosis of mycetoma by double diffusion in agar. Sabouraudia. 1968;6:106–10.PubMedGoogle Scholar
  96. 96.
    Gumma SA, Mahgoub ES. Counterimmunoelectrophoresis in the diagnosis of mycetoma and its sensitivity as compared to immunodiffusion. Sabouraudia. 1975;13:309–15.Google Scholar
  97. 97.
    Hay RJ, Mackenzie DWR. Mycetoma (madura foot) in the United Kingdom - a survey of forty-four cases. Clin Exp Dermatol. 1983;8:553–62.PubMedCrossRefGoogle Scholar
  98. 98.
    Wethered DB, Markey MA, Hay RJ, Mahgoub ES, Gumma SA. Humoral immune responses to mycetoma organisms: characterization of specific antibodies by the use of enzyme-linked immunosorbent assay and immunoblotting. Trans R Soc Trop Med Hyg. 1988;82:918–23.PubMedCrossRefGoogle Scholar
  99. 99.
    Welsh O. Mycetoma: current concepts in treatment. Int J Dermatol. 1991;30:387–98.PubMedCrossRefGoogle Scholar
  100. 100.
    Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol. 1994;31:S91–102.PubMedCrossRefGoogle Scholar
  101. 101.
    Welsh O, Salinas MC, Rodriguez MA. Treatment of eumycetoma and actinomycetoma. Curr Topics Med Mycol. 1995;6:47–71.Google Scholar
  102. 102.
    Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasi S. Antimycotic susceptibility testing of agents of black grain eumycetoma. J Med Vet Mycol. 1993;31:161–4.PubMedCrossRefGoogle Scholar
  103. 103.
    Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia. 1998;141:73–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009–15.PubMedCrossRefGoogle Scholar
  105. 105.
    Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis. 1998;17:573–5.PubMedGoogle Scholar
  106. 106.
    McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 1998;36:2353–5.PubMedGoogle Scholar
  107. 107.
    Cuenca-Estrella M, Ruiz-Díez B, Martínez-Suárez JV, Monzón A, Rodríguez-Tudela JL. Comparative in-vitro activity of voriconazole (UK-109, 496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 1999;43:149–51.PubMedCrossRefGoogle Scholar
  108. 108.
    Poncio-Mendes R, Negroni R, Bonifaz A, Pappagianis D. New aspects of some endemic mycoses. Med Mycol. 2000;38 suppl 1:237–41.PubMedGoogle Scholar
  109. 109.
    Diaz M, Negroni R, Montero-Gei F, et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin Infect Dis. 1992;14 Suppl 1:S68–76.PubMedGoogle Scholar
  110. 110.
    Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56:745–55.PubMedCrossRefGoogle Scholar
  111. 111.
    Mahgoub ES, Gumma SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg. 1984;78:376–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Symoens J, Moens M, Dom J, et al. An evaluation of two years of clinical experience with ketoconazole. Rev Infect Dis. 1980;2:674–87.PubMedGoogle Scholar
  113. 113.
    Drohuet E, Dupont B. Laboratory and clinical assessment of ketoconazole in deep-seated mycosis. Am J Med. 1983;74:30.CrossRefGoogle Scholar
  114. 114.
    Hay RJ. Ketoconazole in the treatment of fungal infection. Clinical and laboratory studies. Am J Med. 1983;74:16–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Poza G, Montoya J, Redondo C, et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis. 2000;30:981–2.PubMedCrossRefGoogle Scholar
  116. 116.
    Muñoz P, Marín M, Tornero P, Martín-Rabadán P, Rodríguez-Creixems M, Bouza E. Successful outcome of Scedesporiun apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis. 2000;31:1499–501.PubMedCrossRefGoogle Scholar
  117. 117.
    Nesky MA, McDougal EC, Peacock JE. Pseudallesheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallesheriasis. Clin Infect Dis. 2000;31:673–7.PubMedCrossRefGoogle Scholar
  118. 118.
    Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg. 2006;100:891–4.PubMedCrossRefGoogle Scholar
  119. 119.
    Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.PubMedCrossRefGoogle Scholar
  120. 120.
    Lexier R, Walmsley SL. Successful treatment of Madura foot caused by Pseudallescheria boydii with Escherichia coli superinfection: a case report. Can J Surg. 1999;42:307–9.PubMedGoogle Scholar
  121. 121.
    Turner PG. Madura foot or plantar fibromatosis. J Bone Joint Surg Br. 1989;71:531.PubMedGoogle Scholar
  122. 122.
    Queiroz-Telles F, Queiroz-Telles JE. Treatment of paracoccidiodomycosis and Pseudallescheria boydii mycetoma with itraconazole: a preliminary report of two cases. Rev Iberica Micología. 1988;5 Suppl 1:72.Google Scholar
  123. 123.
    Degavre B, Joujoux JM, Dandurand M, Guillot B. First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. J Am Acad Dermatol. 1997;37:318–20.PubMedCrossRefGoogle Scholar
  124. 124.
    Fahal AH, el Hag IA, Gadir AF, el Lider AR, el Hassan AM, Baraka OZ, et al. Blood supply and vasculature of mycetoma. J Med Vet Mycol. 1997;35:101–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Instituto de Medicina Tropical; “Alexander von Humboldt,”Universidad Peruana Cayetano HerediaLimaPeru
  2. 2.Departamento de Enfermedades Transmisibles y DermatológicasHospital Nacional Cayetano HerediaLimaPeru

Personalised recommendations